Andrew Witty

By doing so we will strongly position GSK to achieve the medium-term outlook set out to investors last year and deliver a return to core earnings growth in 2016.

It would be extremely unwise to do anything in anticipation of that, the chances of us doing something in an accelerated time frame are, I think, extraordinarily low.

If you were asking that question today, based on everything I can see from an external environment, my recommendation would probably be not to change the status quo. But obviously at a different date in the future you may come to a different conclusion to that question.

We are well on the way and at the end of that journey it gives us options, i think it is the right thing for us to be talking about. It requires a certain level of acceptance of the uncertain - we are not giving you a definite 'Yes' or 'No'.

For the first time at GSK we have created a business which has the potential to be of sufficient scale that you could imagine that one day it could be separate.

While RTS,S on its own is not the complete answer to malaria, its use alongside those interventions ... such as bed nets and insecticides would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most.

While RTS,S on its own is not the complete answer to malaria, its use alongside those interventions currently available such as bed nets and insecticides would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most.

We've decided we're not going to play. We've consciously had a think about it but we're not going to play, of course, it's definitely taken a bit of our market, no question at all -- but there's a lot of competition in that space anyway.